We are a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Our platform of products provides effective and easy-to-use solutions designed to simplify everything from diagnosis and patient selection, to complex case revisions and post-operative care. Our three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat, or ENT, physicians to conveniently and comfortably perform a broad range of procedures in the ENT physician office and to simplify operating room-based treatment. When used as a stand-alone therapy in the physician’s office, our XprESS balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery, or FESS, the primary surgical treatment for chronic and recurrent sinusitis. Patients treated with our products in this trial in the ENT physician office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS. We estimate that physicians have treated over 150,000 patients with our XprESS products since the launch of the first XprESS product in February 2010. Our addressable patient population consists of a portion of patients who undergo FESS, as well as patients who fail medical management but do not undergo sinus surgery. We estimate the annual total addressable market for our products in the United States is approximately 690,000 patients, which, based on our estimate of the average revenue per procedure in the balloon sinus dilation market, represents an annual market opportunity of approximately $1.0 billion.
Company profile
Ticker
ENTL
Exchange
Website
CEO
Robert S. White
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
ENTL stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
12 Mar 18
EFFECT
Notice of effectiveness
6 Mar 18
EFFECT
Notice of effectiveness
6 Mar 18
25-NSE
Exchange delisting
28 Feb 18
8-K
Termination of a Material Definitive Agreement
28 Feb 18
POS AM
Prospectus update (post-effective amendment)
28 Feb 18
POS AM
Prospectus update (post-effective amendment)
28 Feb 18
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Feb 18
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Feb 18
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Feb 18
Latest ownership filings
SC 13G
Entellus Medical Inc
1 Feb 19
SC 13D/A
Entellus Medical Inc
8 Mar 18
SC 13D/A
Entellus Medical Inc
7 Mar 18
SC 13D/A
Entellus Medical Inc
2 Mar 18
4
Joshua J Baltzell
1 Mar 18
4
Brent Moen
1 Mar 18
4
JOHN K BAKEWELL
1 Mar 18
4
Shawn McCormick
1 Mar 18
4
Brian E Farley
1 Mar 18
4
ROBERT S. WHITE
1 Mar 18
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|